 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LZM-005 / Livzon Pharma
P1 data, Journal, Metastases: Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. (Pubmed Central) - Dec 28, 2022
Biomarker analysis showed that chromatin remodeling genes KMT2B and BRWD1 were associated with better progression-free survival. LZM005 is well tolerated and shows potent activity in patients with HER2-positive MBC.
- LZM-005 / Livzon Pharma, Herceptin (trastuzumab) / Roche
[VIRTUAL] Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1337;
LZM005 was well tolerated and showed potent activity in patients with HER2-positive metastatic breast cancer . Further evaluation was warranted.